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Background
Atrial fibrillation is a commonly encountered clinical 
problem. Although a large percentage of patients have no 
clearly identifiable precipitant, secondary atrial fibrillation is a 
well-documented clinical entity.1
Case presentation
A 73-year-old female with a history of obstructive sleep apnea, 
hypertension, and chronic obstructive pulmonary disease 
presents with complaints of intermittent palpitations, substernal 
squeezing chest pressure, and shortness of breath for two weeks. 
Her most recent episode occurred on the bus, prompting her to 
come to the emergency room for evaluation. Further questioning 
revealed mild weight loss and diarrhea over the prior few weeks. 
Home medications included amlodipine, baby aspirin, albuterol 
as needed, and ciprofloxacin for a recently diagnosed URI.
Investigation
Vital signs were temperature 99.4°F, blood pressure 140/70, 
heart rate 154, respiratory rate 14, with oxygen saturation of 
95% on room air. Physical exam revealed scattered bilateral 
rhonchi, irregularly irregular tachycardia, and mild lower 
extremity edema. Electrocardiogram (ECG) showed atrial 
fibrillation with a ventricular rate of 137 bpm and non-specific 
ST/T wave changes. Initial laboratory studies showed negative 
cardiac markers, normal blood counts, and normal basic 
metabolic panel. Transthoracic echocardiogram on hospital day 
1 was remarkable for a normal ejection fraction (65%) without 
segmental wall motion abnormalities, severely dilated left 
atrium (left atrial volume Index 43 cc/m2), mild left ventricular 
hypertrophy, and no significant valvular abnormalities.
Further lab studies revealed a thyroid-stimulating hormone 
(TSH) less than 0.01mIU/mL and free thyroxine (fT4) of 4.1 
ng/dL (0.7-1.7 ng/dL). Endocrinology was consulted and 
recommended empirically starting methimazole 10 mg three 
times a day along with further thyroid laboratory investigation, 
and a thyroid ultrasound. Total triiodothronine (T3) was 
325ng/dL (90-180ng/dL), free T3 was 15.3pg/dL (2-4.4 pg/
dL), and thyroid ultrasound revealed a rounded homogeneous 
thyroid without any dominant nodules greater than1cm. A 
thyroid uptake scan (Figure 1) exhibited rapid iodine turnover 
consistent with Graves’ disease. Eventually, thyroid stimulating 
immunoglobulin returned at a level of 620% (normal <140%) 
and anti-thyroid peroxidase antibody level was 530.5 units 
(0-100 units).
Treatment
The patient’s heart rate was initially controlled with intravenous 
beta-blockers. She was fully anticoagulated for her new-onset 
atrial fibrillation. The patient’s rate control improved with oral 
metoprolol in addition to methimazole. She spontaneously 
converted to sinus rhythm on treatment day 3 of this regimen. 
Her heart rhythm remained in sinus throughout the rest of 
her hospitalization, and she was discharged with a enoxaparin 
to warfarin. She was asked to follow-up with endocrinology 
as an outpatient to discuss further treatment options for her 
hyperthyroidism, including possible radioactive ablation. 
Outcome and follow-up
The patient has been seen in follow-up in the cardiology clinic. 
Office exam and ECG revealed frequent atrial ectopy and it 
is possible that this patient has subclinical paroxysmal atrial 
fibrillation episodes. She is rate controlled with metoprolol and 
is anticoagulated with warfarin, which she is to continue for three 
months. After three months, a one week outpatient telemetry 
will be ordered to assess her burden of atrial fibrillation. Should 
she be free of atrial fibrillation, the possibility of discontinuing 
her warfarin and maintaining her on aspirin mono-therapy will 
be discussed with the patient.
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Figure 1. Thyroid uptake scan showing diffuse thyroid uptake 
without a dominant “hot” nodule. These findings are consistent 
with Graves’ disease.
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Discussion
Atrial fibrillation is the most common arrhythmia in patients 
with thyrotoxicosis. Prevalence of atrial fibrillation in hyperthy-
roidism ranges between less than 2% to 20%.1,2 Increasing 
age, male sex and structural heart disease, such as ischemic 
heart disease, congestive heart failure and valvular disorders 
(especially mitral valve prolapse), are associated with increased 
risk of atrial fibrillation in patients with hyperthyroidism.3 
While it is common for hyperthyroid patients to develop atrial 
fibrillation, less than 1% of all atrial fibrillation patients have 
hyperthyroidism.4
The mechanism by which hyperthyroidism predisposes to atrial 
fibrillation has not been clearly identified.1 Thyroid hormone 
shortens cardiomyocyte refractory period by upregulating the 
transcription of β-adrenergic receptors, resulting in an increased 
cAMP that subsequently accelerates diastolic depolarization 
and increases heart rate. Thyroid hormone shortens the action 
potential duration of isolated rabbit pulmonary vein cardiomy-
ocytes, which decreases refractoriness and facilitates the genesis 
of reentrant circuits, thereby increasing the arrhythmogenic 
activity of pulmonary vein cardiomyocytes.5 
The cardiovascular manifestations of hyperthyroidism are 
best corrected by treating the underlying thyrotoxicosis with 
either antithyroid drug therapy or radioactive iodine thyroid 
ablation.1 Pharmacotherapy with methimazole or propylthio-
uracil can provide a more rapid reduction in serum T4 and T3 
than radioactive iodine ablation and is often utilized to prevent 
the potential thyrotoxicosis exacerbation that can occur with 
therapeutic doses of radioidodine.6 Methimazole is typically 
preferred to propylthiouracil, except during the first trimester 
of pregnancy, because it can more rapidly reverse thyrotoxicosis 
and has fewer side effects. Both serum T4 and T3 should be 
monitored in the treatment of thyrotoxicosis because serum T3 
concentrations may remain elevated even with normalization 
of serum T4.7 In comparison with the importance of serum T3 
and T4 values, serum TSH values may be misleading during the 
initial period of treatment.8
Patients under 60 years of age without preexisting heart disease 
and short duration thyrotoxicosis typically spontaneously 
convert to normal sinus rhythm within 6 weeks; the frequency 
of conversion decreases in older patient populations, who 
frequently require interventions.9 The treatment of atrial 
fibrillation in thyrotoxicosis should be limited to rate control, 
as cardioversion and normal sinus rhythm cannot be reliably 
maintained while thyrotoxicosis persists.1 Patients who 
experience atrial fibrillation as a complication of thyrotox-
icosis are at increased risk of thromboembolism, and should 
be anticoagulated according to non-valvular atrial fibrillation 
guidelines. Because thyrotoxicosis is associated with increased 
plasma clearance of vitamin K-dependent coagulation factors, 
the dose of warfarin required to achieve full anticoagulation in 
these patients is lower.10
Key Points
Patients presenting with arrhythmias should be screened for 
thyroid dysfunction. These arrhythmias are best corrected 
with treatment of underlying thyroid disease. Atrial fibrillation 
secondary to thyrotoxicosis should be treated with rate control, 
as cardioversion cannot reliably maintain sinus rhythm.
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